Pfizer’s drug meets main goal in late-stage blood cancer trial
By Thomson ReutersMar 12, 2024 | 5:59 AM
(Reuters) – Pfizer said on Tuesday a combination treatment using its drug, Adcetris, met its main goal of overall survival when tested in patients with a type of blood cancer.
(Reporting by Pratik Jain; Editing by Shailesh Kuber)
For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.
